<DOC>
	<DOCNO>NCT03081494</DOCNO>
	<brief_summary>This phase Ib study PDR001 combination regorafenib adult patient previously treat metastatic microsatellite stable ( MSS ) colorectal cancer . The study assess primarily safety tolerability efficacy PDR001 combination regorafenib . Particular attention pay level activity study drug combination CMS4 patient ( retrospective analysis ) .</brief_summary>
	<brief_title>Phase Ib Study PDR001 Combination With Regorafenib Adult Patients With Previously Treated Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Key inclusion criterion : 1 . Patients metastatic colorectal adenocarcinoma . 2 . Patients must provide newly obtain archival tumor sample correspond CRC diagnosis ( primary tumor ) sufficient tissue quality ( qualify ) analysis 3 . Patients must provide newly obtain tumor tissue sample metastatic site 4 . Patients presence least one lesion measurable disease per RECIST 5 . Patients previously treat two prior regimen per standard care experienced disease progression ( include VEGF EGFR target therapy ( KRAS wild ) . 6 . Patient Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Key exclusion criterion : 1 . Patients MSIH colorectal adenocarcinoma define per local assessment use standard care test 2 . Patients metastatic disease amenable resect potentially curative surgery 3 . Patients chemotherapy , radiation , biological cancer therapy within 14 day prior first dose study treatment 4 . Patients history prior treatment antiPD1 , antiPDL1 , antiPDL2 , anti CTLA4 antibody , checkpoint inhibitor Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PDR001</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>regorafenib</keyword>
	<keyword>CRC</keyword>
	<keyword>MMS</keyword>
	<keyword>CMS4</keyword>
	<keyword>ElevatION : CRC-102</keyword>
</DOC>